Tenaya Therapeutics (TNYA) Accumulated Expenses (2020 - 2026)

Tenaya Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 18.53% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (up 18.53% YoY), while the FY2025 annual figure was $8.8 million, up 9.96% from the prior year.
• Accumulated Expenses was $1.9 million for Q1 2026 at Tenaya Therapeutics, down from $8.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $10.7 million in Q4 2022 to a low of $1.6 million in Q1 2025.
• Historically, Accumulated Expenses has averaged $6.2 million across 5 years, with a median of $7.4 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses soared 704.22% in 2022, then plunged 80.94% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $10.7 million in 2022, then tumbled by 75.78% to $2.6 million in 2023, then soared by 211.07% to $8.0 million in 2024, then advanced by 9.96% to $8.8 million in 2025, then tumbled by 78.28% to $1.9 million in 2026.
• The last three Accumulated Expenses figures came in at $1.9 million (Q1 2026), $8.8 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.